Rotation des biothérapies en cas de réponse inadéquate à un premier agent biologique dans la polyarthrite rhumatoïde

During the last years, the treatment strategy of rheumatoid arthritis (RA) patients has been largely improved due to the discovery of biological treatment. These agents have been developed based on a better understanding of the physiopathology of the disease. However, a proportion of the RA population does not benefit or escape to these therapies. Therefore, these patients switch from one agent to another one and the aim of this article is to review the data in this context of failure. The best strategy for a biological treatment in established RA will be discussed.